Cargando…
Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort
Pathogenic germline variants in the protection of telomeres 1 gene (POT1) have been associated with predisposition to a range of tumour types, including melanoma, glioma, leukaemia and cardiac angiosarcoma. We sequenced all coding exons of the POT1 gene in 2928 European-descent melanoma cases and 32...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279804/ https://www.ncbi.nlm.nih.gov/pubmed/36539277 http://dx.doi.org/10.1136/jmg-2022-108776 |
_version_ | 1785060667193032704 |
---|---|
author | Simonin-Wilmer, Irving Ossio, Raul Leddin, Emmett M Harland, Mark Pooley, Karen A Martil de la Garza, Mauricio Gerardo Obolenski, Sofia Hewinson, James Wong, Chi C Iyer, Vivek Taylor, John C Newton-Bishop, Julia A Bishop, D Timothy Cisneros, Gerardo Andrés Iles, Mark M Adams, David J Robles-Espinoza, Carla Daniela |
author_facet | Simonin-Wilmer, Irving Ossio, Raul Leddin, Emmett M Harland, Mark Pooley, Karen A Martil de la Garza, Mauricio Gerardo Obolenski, Sofia Hewinson, James Wong, Chi C Iyer, Vivek Taylor, John C Newton-Bishop, Julia A Bishop, D Timothy Cisneros, Gerardo Andrés Iles, Mark M Adams, David J Robles-Espinoza, Carla Daniela |
author_sort | Simonin-Wilmer, Irving |
collection | PubMed |
description | Pathogenic germline variants in the protection of telomeres 1 gene (POT1) have been associated with predisposition to a range of tumour types, including melanoma, glioma, leukaemia and cardiac angiosarcoma. We sequenced all coding exons of the POT1 gene in 2928 European-descent melanoma cases and 3298 controls, identifying 43 protein-changing genetic variants. We performed POT1-telomere binding assays for all missense and stop-gained variants, finding nine variants that impair or disrupt protein–telomere complex formation, and we further define the role of variants in the regulation of telomere length and complex formation through molecular dynamics simulations. We determine that POT1 coding variants are a minor contributor to melanoma burden in the general population, with only about 0.5% of melanoma cases carrying germline pathogenic variants in this gene, but should be screened in individuals with a strong family history of melanoma and/or multiple malignancies. |
format | Online Article Text |
id | pubmed-10279804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-102798042023-07-01 Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort Simonin-Wilmer, Irving Ossio, Raul Leddin, Emmett M Harland, Mark Pooley, Karen A Martil de la Garza, Mauricio Gerardo Obolenski, Sofia Hewinson, James Wong, Chi C Iyer, Vivek Taylor, John C Newton-Bishop, Julia A Bishop, D Timothy Cisneros, Gerardo Andrés Iles, Mark M Adams, David J Robles-Espinoza, Carla Daniela J Med Genet Cancer Genetics Pathogenic germline variants in the protection of telomeres 1 gene (POT1) have been associated with predisposition to a range of tumour types, including melanoma, glioma, leukaemia and cardiac angiosarcoma. We sequenced all coding exons of the POT1 gene in 2928 European-descent melanoma cases and 3298 controls, identifying 43 protein-changing genetic variants. We performed POT1-telomere binding assays for all missense and stop-gained variants, finding nine variants that impair or disrupt protein–telomere complex formation, and we further define the role of variants in the regulation of telomere length and complex formation through molecular dynamics simulations. We determine that POT1 coding variants are a minor contributor to melanoma burden in the general population, with only about 0.5% of melanoma cases carrying germline pathogenic variants in this gene, but should be screened in individuals with a strong family history of melanoma and/or multiple malignancies. BMJ Publishing Group 2023-07 2022-12-20 /pmc/articles/PMC10279804/ /pubmed/36539277 http://dx.doi.org/10.1136/jmg-2022-108776 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Cancer Genetics Simonin-Wilmer, Irving Ossio, Raul Leddin, Emmett M Harland, Mark Pooley, Karen A Martil de la Garza, Mauricio Gerardo Obolenski, Sofia Hewinson, James Wong, Chi C Iyer, Vivek Taylor, John C Newton-Bishop, Julia A Bishop, D Timothy Cisneros, Gerardo Andrés Iles, Mark M Adams, David J Robles-Espinoza, Carla Daniela Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title | Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title_full | Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title_fullStr | Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title_full_unstemmed | Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title_short | Population-based analysis of POT1 variants in a cutaneous melanoma case–control cohort |
title_sort | population-based analysis of pot1 variants in a cutaneous melanoma case–control cohort |
topic | Cancer Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279804/ https://www.ncbi.nlm.nih.gov/pubmed/36539277 http://dx.doi.org/10.1136/jmg-2022-108776 |
work_keys_str_mv | AT simoninwilmerirving populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT ossioraul populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT leddinemmettm populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT harlandmark populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT pooleykarena populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT martildelagarzamauriciogerardo populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT obolenskisofia populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT hewinsonjames populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT wongchic populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT iyervivek populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT taylorjohnc populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT newtonbishopjuliaa populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT bishopdtimothy populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT cisnerosgerardoandres populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT ilesmarkm populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT adamsdavidj populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort AT roblesespinozacarladaniela populationbasedanalysisofpot1variantsinacutaneousmelanomacasecontrolcohort |